Zinc finger and BTB domain-containing protein 31 (MYNN)

Zinc finger and BTB domain-containing protein 31 (MYNN) is a transcription factor belonging to the BTB/POZ and zinc finger protein family[1][7]. It contains a BTB/POZ domain, which mediates protein–protein interactions and recruitment of co-repressors or chromatin regulators, and multiple C2H2-type zinc finger domains, which mediate DNA binding[1][2][6]. MYNN regulates gene expression through direct DNA interaction as well as chromatin remodeling, often acting as a transcriptional repressor but potentially context-dependent in function[1][2]. Alternative splicing results in multiple transcript variants for MYNN, and a pseudogene is present on chromosome 14[1]. Its best-established biological roles are in gene expression regulation and chromatin modification, with sparse or no evidence supporting its status as a direct therapeutic target or druggable protein in current biomedical literature[1][7].\n\nNotes:\n- There are no known or established interacting drugs, mechanisms of drug action, validated biomarkers, or clinical safety concerns for MYNN at present[1][7].\n- MYNN has no established role as a therapeutic target (receptor, enzyme, transporter, etc.) but is primarily classified as a transcription factor involved in normal gene regulation[1].\n- The name and synonym assignment follows best practices per UniProt and NCBI Gene[1][7].\n- No credible evidence of misspelling or incorrectness in the supplied target information.

Other names

MyoneurinMYNNOSZFZBTB31SBBIZ1ZNF902zinc finger and BTB domain-containing protein 31zinc finger protein with BTB/POZ domain